Leerink Partnrs Issues Negative Estimate for FDMT Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Stock analysts at Leerink Partnrs lowered their Q3 2025 earnings per share (EPS) estimates for 4D Molecular Therapeutics in a report issued on Monday, August 11th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($0.98) per share for the quarter, down from their prior estimate of ($0.88). The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for 4D Molecular Therapeutics’ Q4 2025 earnings at ($0.94) EPS, FY2025 earnings at ($3.82) EPS and FY2026 earnings at ($3.79) EPS.

Several other brokerages have also recently commented on FDMT. Roth Capital dropped their target price on 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday. Barclays dropped their target price on 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a report on Friday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Tuesday, July 29th. The Goldman Sachs Group dropped their target price on 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating on the stock in a report on Friday, May 9th. Finally, Chardan Capital reissued a “buy” rating and set a $25.00 target price on shares of 4D Molecular Therapeutics in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $30.40.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ:FDMT opened at $7.10 on Thursday. 4D Molecular Therapeutics has a 12 month low of $2.23 and a 12 month high of $17.41. The stock has a market cap of $331.57 million, a price-to-earnings ratio of -2.01 and a beta of 2.83. The stock’s 50 day moving average price is $4.62 and its 200 day moving average price is $4.13.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.10). 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.52 million.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of 4D Molecular Therapeutics during the 4th quarter valued at $50,000. Velan Capital Investment Management LP acquired a new stake in shares of 4D Molecular Therapeutics during the 4th quarter valued at $56,000. Virtus ETF Advisers LLC grew its position in 4D Molecular Therapeutics by 173.9% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,333 shares of the company’s stock worth $58,000 after purchasing an additional 6,560 shares in the last quarter. Quadrature Capital Ltd purchased a new position in 4D Molecular Therapeutics during the 2nd quarter worth approximately $42,000. Finally, Los Angeles Capital Management LLC purchased a new position in 4D Molecular Therapeutics during the 2nd quarter worth approximately $42,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.